"Dermatologic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used to treat or prevent skin disorders or for the routine care of skin.
| Descriptor ID |
D003879
|
| MeSH Number(s) |
D27.505.954.444
|
| Concept/Terms |
Dermatologic Agents- Dermatologic Agents
- Dermatological Agents
- Agents, Dermatological
- Agents, Dermatologic
- Dermatologic Agent
- Agent, Dermatologic
- Agent, Dermatological
- Dermatological Agent
|
Below are MeSH descriptors whose meaning is more general than "Dermatologic Agents".
Below are MeSH descriptors whose meaning is more specific than "Dermatologic Agents".
This graph shows the total number of publications written about "Dermatologic Agents" by people in this website by year, and whether "Dermatologic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 3 | 0 | 3 |
| 2005 | 3 | 0 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 1 | 3 |
| 2010 | 1 | 0 | 1 |
| 2011 | 3 | 0 | 3 |
| 2012 | 3 | 1 | 4 |
| 2013 | 4 | 0 | 4 |
| 2014 | 3 | 1 | 4 |
| 2015 | 2 | 0 | 2 |
| 2016 | 2 | 1 | 3 |
| 2017 | 10 | 0 | 10 |
| 2018 | 8 | 1 | 9 |
| 2019 | 6 | 1 | 7 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 1 | 1 | 2 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dermatologic Agents" by people in Profiles.
-
Topical Therapies for Atopic Dermatitis. JAMA. 2023 11 14; 330(18):1791-1792.
-
Gender differences in isotretinoin prescriptions during the COVID-19 pandemic at a U.S. academic medical center. Arch Dermatol Res. 2023 Apr; 315(3):643-645.
-
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023 01; 88(1):40-51.
-
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021 02 06; 397(10273):487-498.
-
Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021 Feb; 84(2):432-470.
-
Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study. J Eur Acad Dermatol Venereol. 2020 Feb; 34(2):301-309.
-
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020 Jan; 82(1):161-201.
-
Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience. Expert Opin Biol Ther. 2020 01; 20(1):95-104.
-
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. Qual Life Res. 2020 Feb; 29(2):369-380.
-
Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts. J Eur Acad Dermatol Venereol. 2020 Jan; 34(1):112-118.